

From: SANTE C3 HSC
Sent: mercredi 14 juillet 2021 14:25
To: SANTE C3 HSC
Subject: Fourth update of the RAT common list + follow-up questions
Attachments: HSC_Common RAT list_4th update_Agreed_140721_.pdf; HSC_Common RAT list_4th update_Agreed_140721_TC.docx

Dear members of the HSC,
Dear colleagues,

Please find enclosed the fourth update of the EU common list of rapid antigen tests, as agreed today by the Health Security Committee. For ease of reference, we have also included a version in track changes so you can swiftly identify the amendments made.

Secondly, as a follow up to today's meeting, please find below two questions linked to lab-based antigenic assays. We would be grateful if you could send us your replies by **Friday 16 July COB**. Your replies will be used to further inform the discussions of the TWG meeting next week Tue.

- **Should the lab-based antigenic assays be included in Annex I (e.g. a separate section as part of the annex) or should we list them in a new Annex?** Please take into account whether or not your country is intending to use these types of assays in the context of travel/the DCC. The legal text of the Digital COVID Certificate is currently referring to the common list (annex I) as follows:
 - "A certificate confirming that the holder has been subject to a NAAT test or a rapid antigen test listed in the common and updated list of COVID-19 rapid antigen tests established on the basis of the Council Recommendation of 21 January 2021"
- **Should saliva lab-based antigenic assays be included in the common list?** Experts and the HSC agreed last week that rapid antigen tests based on saliva sampling should *not* be included in the common list – should the same apply to lab-based antigenic assays using saliva sampling?

Thank you in advance.

Kind regards,
HSC Secretariat